1H-MRS 375

2-deoxyglucose 85

3,3′-diindolylmethane (DIM) 1269

3D culture systems 2342

450K Infinium Methylation BeadChip 781

ABCC10 696

abiraterone 2248

abiraterone acetate 1249

ABO blood type 174

access to healthcare 577

acetylation 61, 568

acinar to ductal metaplasia 817

acrylamide 987

acute promyelocytic leukaemia 874

adenocarcinoma 1993

adjuvant chemotherapy 1004, 1275

adjuvant intraperitoneal chemotherapy 1112

adjuvant systemic treatment 837

adjuvant therapy 1917

advanced basal cell carcinoma 1476

advanced gastric cancer 660

advanced solid tumours 651, 2268

afatinib 1750

α-galactosylceramide 1945

age-period-cohort models 965

AHEI 1454

AICAR 1562

Akt 101, 817

AKT isoforms 2103

alcohol 203

alcohol intake 186

ALDH1 486

aliphatic solvents 998

allograft 696

all-trans retinoic acid 874

alpha-enolase 799

ALU-qPCR 1482

aMED 1454

AMOT-p80 807

AMPK 25

anal canal carcinoma 1726

anal cancer 1726

androgen metabolism 1249

androgen receptor 1249, 2248

aneuploidy 1780

angiogenesis 25, 68, 477, 497, 559, 1605, 2275

angiogenin 1742

animal model 708

Annexin A2 2328

antagonistic effect 1310

anti-angiogenic therapy 1350

antiangiogenic therapy 68

anti-CTLA4 2214

anti-glycan antibodies 1634

anti-PD-1 2214

anti-PD-L1 2214

anti-tumour response 1350

apoptosis 101, 395, 1327, 1552, 2275

argpyrimidine 395

aromatase inhibitor 46, 2046

aromatic solvents 998

arsenic trioxide 874

artificial olfactory system 1213

α-SMA 1917

asparaginase 1159

aspirin 61, 623, 2172

aspirin use 1852

astrocyte elevated gene-1 166

AT7519 2262

atypical glandular cells of uncertain significance 851

Aurora B 2142

autophagy 309, 375, 944, 1562

AZD2171 1590

BAP1 1373

β-arrestin1 568

basal cell carcinoma 203

basal like 1532

basal-like breast cancer 326

β-catenin 1159

BCON 437

BCR/ABL 568

benzene 998

bevacizumab 25, 241, 497, 1241, 2051

BI-69A11 101

biliary tract cancer 430

bioenergetics 85

biomarker 25, 444, 437, 551, 781, 799, 828, 918, 1201, 1381, 1614, 1977, 2242

biomolecules 61

biopsy 1201

bioreactor 2342

birth residence 1814

bladder cancer 437, 1870, 2103

blood pressure 1909

blood serum 909

BMS-936559 2214

body weights and measures 203, 207

borderline glandular cells 851

bosutinib 2058

bowel cancer 1440, 1734

BRAF 292, 640

BRAF inhibitors 292

brain cancer 1255

BRCA1 1269, 2351

BRCA1 BRCA2 mutations 1132

BRCA2 1238, 2351

BRCAX 2351

breast cancer 1004, 1060, 1065, 1241, 1269, 1532, 1542, 46, 157, 300, 326, 532, 539, 619, 623, 696, 837, 894, 918, 1552, 1836, 1881, 1945, 2046, 2242

cancer stem cells 365, 486, 506, 1572, 2122

cancer survivors 1718, 1899

cancer therapy 68, 1562

cancer-associated fibroblasts 763, 1230, 2082

cancer-testis antigens 909

capecitabine 265, 1726, 2058

carbohydrate metabolism 559

carcinoembryonic antigen 1482

carcinogenesis 1448

carcinoid heart disease 1703

carcinoma-like associated fibroblasts 1625

case-control 981

caspase-10 1955

caspase-8 1955

castration-resistant prostate cancer 1802, 2248

catumaxomab 1519

cause of death 1014

CBX2 1663

CCNG2 1572

CCSK 227

CD10 506

CD11b+ myeloid cells 1509

CD133 365, 486

CD276 149

CD44 variant 2 365

CD77 1634

CD8+ T cell 1391

CDKN2C 407

cediranib 1590

celecoxib 46

cell culture 1021

cell cycle 1319

cell line 1021

cell line misidentification 1021

cell proliferation 85

cell surface antigen array 506

cell–cell adhesion 1230

central nervous system 1072

central nervous system prophylaxis 1072

cervical cancer 112, 965, 2187

cervical cancer screening 1095

cervical intraepithelial neoplasia 1824

cetuximab 1310

Charlson Index 220

chemokines 1625

chemoprevetion 61

chemoradiotherapy 234, 1509, 1726, 1924

chemoresistance 339, 506, 799, 1552, 1572, 1750

chemoresponse assay 843

chemosensitivity 1150

chemosensitivity assay 843

chemotherapy resistance 955

childhood cancer 998, 1262, 1413, 1814

chlorinated solvents 998

cholangiocarcinoma 430, 1275

cholesterol 1139

chromosome 9p 1381

chromosome instability 2142, 1780

chronic liver disease 2163, 2220

chronic myeloid leukaemia (CML) 568

circulating cell-free DNA 1482

circulating endothelial cells (CEC) 149, 1742

circulating microRNAs 909

circulating RNA 909

cisplatin 339, 515, 799, 2268

clear cell 1381

clear cell sarcoma of the kidney 227

clinical features 227

clinical outcome 1293

clinical trial 589, 1060

clinical trial recruitment 1

clinicopathological factor 539

CML 1080

CNS cancer 1413

cognitive probing 1262

cohort 181, 987

cohort studies 207, 1490, 1836

colon adenocarcinoma 883

colon cancer 61, 174, 1285

colorectal adenocarcinoma 1985

colorectal adenoma 1985

colorectal cancer 25, 241, 365, 461, 497, 577, 598, 667, 736, 749, 970, 1112, 1122, 1391, 1482, 1590, 1605, 1657, 1742, 1765, 1932, 1965, 2076, 2082, 2152, 2172, 2287

colorectal cancer progression 927

colorectal cancer screening 1734

colorectal carcinoma 101, 1977

colorectal liver metastases 470

colorectal neoplasms/diagnosis 1490, 2156

combination therapy 2039

comorbidities 203, 220

concordance 1526

CONKO-001 1917

Connexin 32 132

connexin channel permeability 125

connexin26/connexin32 125

content validity 1262

contralateral breast cancer 1004

controlled release 708

copy number variations 2014

cost-effectiveness 1542, 1693, 1734

COUP-TFII 933

COX-2 46

CPRD 1410

CRAF 640

CRC 726

CRM1 281

cryostorage 1021

cryotherapy 424

CSPP1 326

cutaneous squamous cell carcinoma 640

cyclin-dependent kinase 2262

cyclooxygenase-2 125

cystectomy 444

cytarabine 1072

cytochrome P450 2287

cytokines 1625

cytological examination 2235

cytoreductive surgery 1500

dalotuzumab 1932

dasatinib 1310

DCIS 46

decision aids 1

decision curve 1526

decisional conflict 1

decoy receptor fusion protein 68

dedifferentiation 2082

dendritic cells 1605

deprivation 2152, 589

desmoplastic reaction 2082

dexamethasone 2248

diabetes 181, 1432, 1836

diagnostic biomarker 726

dichloroacetate 375

dietary intake 1870

dietary patterns 1454

differentiation 883

diffuse large B- cell lymphoma 1072

discrimination 1526

disease stage 461

disease-free survival 166

distant recurrence 166

DLBCL 55

DNA damage 1319

DNA damage response 1293

DNA integrity index 1482

DNA methylation 1095, 1581, 781

DNA methylation biomarker 525

DNA mismatch repair 823

DNA repair 94

docetaxel 696, 955

dose 2067

draining lymph node 1391

drug development 1305, 828

drug resistance 1150

drug resistance and MDR2 486

ductal carcinoma 619

early detection of cancer 2156

early prognostic value 726

EBV DNA 1102

efficacy 1519

EGFR 749, 894, 2033

EGFR gene mutations 413

elastin 139

elderly 220, 241, 2224

embryonic stem cell 1054

emergencies 1490

emergency admission 577, 1490

EMT 955, 1363

endocrine therapy 918, 2046

endometrial cancer 78, 674, 987, 1432, 1750

endometrial cancer risk 186

endostatin 1605

endothelial cell 559, 149

endothelial progenitor cells 1742

endotoxin 603

enhancer of zeste homologue 2 (EZH2) 568

enzalutamide 1249

enzymes 1249

EpCAM 955

Eph receptors 1255

EPIC 1870

epidermal growth factor 2067

epidermal growth factor receptor 430, 1065, 2328

epi-drugs 2039

epigenetic changes 1293

epithelial ovarian cancer 1519

epithelial–mesenchymal transition 112, 355, 2082

equipoise 424

ERα 395

Erbb-2 1888

eribulin mesylate (E7389) 2268

ERK 763, 1400, 2103

ERK1/2 395, 2142

erlotinib 2067

erythropoiesis-stimulating agents 33

ESDN/DCBLD2 386

ethanolamine 1646

ethnicity 1440

Etn phosphoglycerides 1646

European Deprivation Index 2152

exemestane 46

exhaustion 1391

exocrine pancreatic cancer 1132

exome sequencing 1657

expression 955, 1581, 1663

expression signature 386

extended lymph node dissection 213

extracapsular spread 2114

extracellular matrix 559

extrahepatic cholangiocarcinoma 1363

faecal blood test (gFOBt) 1440

familial 598

familial breast cancer 2361

fascin 1552

FAZA 2254

Fbxw7 1054

FCCTX 598

feasibility 17

FGF-2 68

fibrinogen 1102

ficlatuzumab 272

flavonoids 1870

flowytometry 149

fluorescence in situ hybridisation 1381

fluorouracil 1726

folate receptor alpha 2297

follow-up care 1899

FOXP3 1581

FRA 2297

gamma-glutamyltransferase 1526

gastric cancer 763

gastric diseases 2180

gastrointestinal stromal tumours 2091

Gb3 (Pk) 1634

Gb4 (P) 1634

GBM 2275

GC–MS 790, 1213

gemcitabine 318, 858, 1275, 1917

gene expression 407, 781

gene expression profiling 837

general practice 623

general practitioner 2152

genomic instability 125

genomics 1532

geranylgeranyl pyrophosphate synthetase 1562

geriatric oncology 2224

germ cell cancer 8

glioblastoma 1255, 1562

glioma 1255, 1400, 2024

gliomas molecular classification 2024

glucocorticoid receptor 2248

GLUT1 437

glutamine 1159

Glutamine synthetase 1159

glutaminolysis 817

glutathione 1150

glutathione S- transferase 1 1802

glycobiology 559

glycolysis 85, 817, 1757

glyoxalase I 395

Gorlin's syndrome 1476

gossypol 2275

GP 1410

gp130 894

great britain/epidemiology 2156

growth 207

growth inhibition 309

GSH 874

GSTP1 1150

haematopoietic stem cell 1054

haploidentical 1080

HB-EGF 1965

head and neck cancer 790, 807, 1230, 1509, 1852

head and neck squamous cell carcinoma 506, 799, 2122

headspace 1213

Hedgehog 1168

hedgehog pathway inhibitors 1476

hENT1 1275

hepatobiliary diseases 2180

hepatocellular carcinoma 132, 1159, 1327

hepatocyte growth factor 272

hepatocytes 2342

HER2 660

HER2 breast carcinoma 689

HER-2-negative 1060

HER2/Neu 1750, 1977

Herceptin-resistant breast cancer 2328

heterogeneity 2205

HIF-1α 2131, 437

histograms 2205

histological special type 619

histological subtype 532

HNSCC 1955, 807

HO-1 874

homologous recombination 94

hormone therapy 2248

hormone-receptor-positive tumours 2046

hormones 1249

HOX genes 807

HOXB9 883

HOXD10 807

HPV 1448

HR HPV triage 851

HSCT 1080

HSF1 78

Hsp27 395

Hsp90 139

Human Fertilisation and Embryology Act 1021

human hepatocellular carcinomas 132

human papillomavirus 1095, 1824

human tissue 1021

Human Tissue Act 1021

Human Tissue Authority 1021

hyaluronate 559

hypercalcaemia 1410

hyperpolarised 13C-MRS 375

hypertension 1241

hypopharyngeal squamous cell carcinoma 386

hypoxia 2254, 437

IDH mutation 2024

IFNG1581

IGFBP-2 1400

IκBα 1688

IL-12p70 927

IL-22 763

imaging 667

imatinib 2091

immunity 866

immunofluorescence assay 1065

immunohistochemistry 944, 1350, 1363, 1373, 1977, 2287, 2297

immunological subtype and prognosis 532

immunosuppression 203

immunotherapy 2214

in situ hybridisation 1977, 944

incidence 203, 965

induced pluripotent stem cell 1054

inequalities 589

inflammation 444, 2287

inflammatory cell infiltration 1605

inflammatory disease 525

inflammatory parameter 55

informed consent 1

insulin 628, 1710

integrin β1 1400

intensity-modulated radiotherapy 1726

interdigitating 1924

internal carotid artery 2229

Intervention Study-II (IBIS-II) 1

intestinal stem cell 1054

intraarterial 1089

intra-arterial chemotherapy 2229

intra-arterial hepatic therapy 255

intraepithelial neoplasia 851

intraoperative 1519

intraperitoneal chemotherapy 1500

intrathecal 1072

intrinsic 1532

invadopodia 539

invasion 139, 763, 1230, 2275, 2308, 2316

invasion OS-9 2131

Ion Proton 2014

Ion Torrent 2014

ionising radiation 395

isoflurane 1338

isoindolinones 716

iTRAQ 799

KDM1A 2039

KDR 407

Kennedy-pathway 318

Ki-67 1222

KIR 1080

KIT 407

KRAS 430, 1213, 1788

Kras-driven cancer 817

Kurtosis 2205

[1-13C]pyruvate 375

lapatinib 1888

large intestine 2076

late presentation 581

LC3 944

LC3B expression 309

leucine-rich-repeat containing G protein-coupled receptor 5 365

leukaemia 1413, 1814

leukaemia-initiating cell 1054

life expectancy 1014

life tables 195

lignans 1870

linoleic acid 318

lipopolysaccharide 603

liposomal doxorubicin 651

liquid biopsy 1614

liquid-based cytology 851

Listeria monocytogenes 1945

liver cancer 132, 255, 1159, 1710, 2163, 2220, 2342

liver metastasis 667, 749

long non-coding RNA 2131

low-grade toxicity 2224

LSD1 2039

luminal-like breast cancer 326

lung adenocarcinoma 339

lung cancer 603, 608, 1213, 1222, 1663, 1843

lung cancer cells 772

lupeol 1327

lymph node 249

lymph node metastasis 213

lymphocytes 444

lymphoid cell 525

Lynch syndrome 598

Macrophages 646, 1509

magnetic resonance imaging 2114

MALAT1 736

male breast cancer 2351

malignant bone marrow plasma cells 1293

mammary carcinoma 2342

mammary tumour 696

mammography 1463, 1542, 1831

MAPK 689, 817, 2033

mass screening 2156, 2187

mast cells 1605

matrix metalloproteinases 1230

MCF-7 cells 395

mCRC 1590

mda-7/IL-24 101

MDM2–p53 antagonists 716

MDR-1 716

Mediterranean diet 981

Mediterranean pattern 1454

MEK inhibitors 292

MEK kinase 1788

MEK162 1788

Melanoma 292, 477

Melphalan 1293

menopausal status 1718

mesenchymal-to-epithelial transition 883

mesothelioma 1860

meta-analysis 33, 680, 976, 1122, 1663, 2172

metabolic addiction 2033

metabolism 318, 817

metadherin 355

metastases 696, 1945

metastasis 355, 807, 883, 933, 1373, 1552, 1663, 1881, 2046, 2058, 2114

metastatic breast cancer 2051

metastatic colorectal cancer 756

metformin 85, 628, 1432, 1710

methionine-L-sulfoximine 1159

methotrexate 1072

methylation 726, 1802

mevalonate pathway 1562

MI-63 716

micro array 1614

microenvironment 646

micronutrients 2163

micropapillary carcinoma 619

microRNA-183 2003

microRNA-21 1285

microsatellite instability 823, 1657

microsatellite repeats 823

migration 696, 2328

miR-1246 1572

miR-125a-5p 2091

miR-146a 807

miR-152 2361

miR-204 2316

miR-21 772

miR-224 339

miR-378a-5p 2142

miR-451a 386

miR-497 2361

miR-646 1188

miRNA 386, 1572, 1614, 1765, 1985, 2091, 2287, 2361

MiSeq 2351

miseq sequencing 1985

mitochondrial respiration 85

mitogen-activated protein kinase pathway 125, 1188

mitosis 2142

MK-0752 1932

MK-2206 1932

MMP-1 1625

MMP-2 139, 1772

moderators 1718

molecular pathogenesis 1780

molecular profiling 17, 532, 1881

molecular subtypes 326

molecular target 1180

molecular target therapy 2103

monitoring 1614

monocarboxylate transporter-1 inhibitor 375

morphine 866

mortality 181, 1014

MPDL3280A 2214

mRECIST 255

MRI 1542, 2205

mRNA expression 1269

MSH3 823

MTDH 166

mTOR 858, 2316

Multidrug Resistance Protein 696

multilevel analysis 2152

multiple myeloma 1293

murine and human PIF receptors 903

mutation 1213, 2014

mutation hotspot 1657

MYC 407

mycoplasma contamination 1021

myeloid cell 525

myeloid-derived suppressor cells 1350

myeloma 628

MYO10 539

nanotechnology 790

nasopharyngeal carcinoma 1102

natural compound and breast cancer 309

neoadjuvant 1060, 1089, 1532

neoplasms 866, 1014, 2058

net survival 195

neural stem cell 1054

neuroblastoma 708, 716

neuroendocrine tumours 1703

neutrophils 444

neutrophil-to-lymphocyte ratio 452

next generation sequencing 1881, 828, 2014

NF-κB 395

NHANES 1448

NICE 1693

nin one binding protein 1188

nintedanib 1060

nivolumab 2214

NK cells 866

NKT cells 1945

nodal yield 213

nomogram 249

non-attendees 2187

non-responders 1095

non-small-cell lung carcinoma 355, 413, 817

nonsteroidal antiinflammatory drugs 1421

NORE1A 2361

Northern Iran 2235

Notch1 799

NRAS 292

Nrf2 874

NSAID 1852

NSCLC 281, 1757

NUAK1 2316

nuclear installation 1814

nucleostemin 2308

Nutlin-3 716

nutrition 987

NVP-LDE225 1168

obesity 1718

occult blood 2156

occupational health 603

oesophageal cancer 234, 1852

oesophageal intraepithelial neoplasia 2003

oesophageal squamous cell carcinoma 1614, 2003, 2235

oestrogen receptor 918

olaparib 651

oligosaccharide 559

oncogene 1657

oncogene addiction 2033

oncogenic Kras 817

oncogenic Kras signalling 817

opioids 866

oral cancer 981

oral hypoglycaemic 1710

oral squamous cell carcinoma (OSCC) 2308

oral squamous cell carcinoma 1230, 2114

organ preservation 2229

ovarian cancer 515, 589, 680, 843, 1634, 1932, 2297

overall survival 452, 909, 1132

overdiagnosis 1463, 1831

oxaliplatin 1924

p21WAF1/CIP1 339

p53 281, 395, 2235

p62/SQSTM1 944

p73 281

paclitaxel 300, 696

PAF 515

PAFR 515

pancreatic cancer 85, 181, 318, 817, 1139, 1572, 1772, 1780, 1788, 1917, 2067, 2180

pancreatic cancer progression models 486

pancreatic ductal adenocarcinoma 2131

pancreatic intraepithelial neoplasia 817

panitumumab 430

paradoxical 640

paranasal sinus carcinoma 2229

PARP 1319

pathological response 470

pathology 918

patient preference 674

patient selection 2156

pazopanib 1909

PD-1 1391

PD2 486

Pdk1 817

pelvic lymph node dissection 213

pelvic lymph node metastasis 112

pemetrexed 220

penectomy 1089

penile cancer 1089

percentiles 2205

pericytes 149

peripheral blood mononuclear cells 1293

peritoneal carcinomatosis 1112, 1500

personalised medicine 17, 843, 1150

pertuzumab 660, 1888

phage display 551

pharmaco-epidemiology 628

pharmacokinetics 660, 2262

pharmacological audit trail 828

pharyngeal cancer 981

phase I trials 265, 858, 828, 1060 1305, 2058, 2262

phase II trials 828

phorbol ester 1646

phospholipase D 1646

physical activity 1718

PI3K 817

PI3K/AKT 2103

PIK3CA 2172, 2351

pilot RCT 234

plasma 1614

platelet-to-lymphocyte ratio 452

platinum 1150

platinum-based therapy 1132

pleural effusion 94

pleural mesothelioma 220

PLX4032 1625

polycomb 1663, 1688

population screening 970

population-based 1836

population-based study 1413

postdiagnosis 2172

postoperative 1519

p-PP2A 756

predictive biomarkers 2103

predictive marker 843

predictive value of tests 2156

prednisolone 2248

preoperative chemoradiotherapy 249

preoperative chemotherapy 470

prevalence 823

prevention 1852

primary care 1410

principal component analysis 1454

prognosis 55, 174, 292, 444, 628, 689, 756, 823, 1201, 1222, 1363, 1373, 1381, 1526, 1663, 1802, 1993, 2091, 2114, 2297, 2308

prognostic 1509

prognostic factors 619

prognostic impact 2024

prognostic index 2051

prognostic markers 78, 365, 749, 1285, 1860

programme evaluation 2156

programmed cell death 4 2003

progression 1703

progression-free survival 1909

proliferation 132, 355, 1222, 2308, 2328

propofol 1338

prospective cohort 2163

prospective study 181, 186

prostate 424, 1663

prostate cancer 213, 781, 955, 1201, 1238, 1249, 1338, 1421

prostate cancer epithelial cell lines 1646

prostate neoplasms 207

protein kinase C 1646

protein synthesis and degradation 903

proteolysis-inducing factor (PIF) 903

provider delay 461

PSA 1238

psychological outcomes 970

psychosocial care 1899

PTBP2 736

PTEN/PI3K/Akt 689

PTGS2 749

PTPN18 2091

pyruvate kinase M2 1757

pyruvate to lactate exchange rate 375

qualitative methods 234

quality assessment 413

quality of health care 2156

quality of life 33, 1718, 1899

quiescence 1054

RAD51 94

radiation bystander effects 125

radiation resistance 1139

radiation-associated 407

radiation-induced bystander effects (RIBEs) 772

radioembolization 265

radio-resistance 506

radiosensitiser 1139

radiotherapy 608, 619, 1310

radon 1413

randomisation 424

randomised controlled trial 1, 976

randomised study 17

randomised trial 2220

rapamycin 858

RAR 2039

rare events 149

rash 2067

RASSF1A 2361

RCC 1047, 1168

reactive oxygen species 395, 772

record linkage 623

rectal cancer 249, 1924

referral 1843

relapse 227

relapse risk 2242

renal cancer 1526

renal cell carcinoma 1188, 1381, 1909, 1047

repeat FOBT 2152

resistance training 8, 1718

retinoic acid receptor 2039

RG7388 716

ridaforolimus 1932

risk communication 1831

risk factor 981, 2051

RRM1 1275

RT–qPCR 1985

salicylic acid 61

salvage 424

sampling error 1201

sarcoma 646, 2091, 2254

scFv antibody 551

screening 577, 965, 1421, 1440, 1542, 2076, 2152, 2235

seasonality 1810

self-sampling 1095, 2187

sensitivity 1734

sensor 790

sequencing 17, 1047

serpinA1 1993

Serpine 2114

serum 2163

SFPQ 736

SHIVA 17

SHP-2 1327

signal transduction 2103

SINE 281

siRNA 1180

sirolimus 858

skeletal muscle 8, 903

skewness 2205

skin cancer 1810

skull base invasion 2229

Smac mimetics 1955

smoking 195, 203

smooth muscle actin 2114

Snail 1993

Snail family transcription factors 933

SNP 1241

social and geographical inequalities 2152

socioeconomic position 608

socioeconomics 1684

SOCS2 726

SOCS6 726

soft tissue sarcoma 1350, 2254

solid tumours 272, 823, 2014

solitary fibrous tumour 1350

SOX2 2122

specificity 1734

splicing 477

Squamous Cell Carcinoma (SCC) 944, 1688

Src 689

SRC inhibition 1310

staging 790

STAT3 763, 894, 927, 1327

STAT5 894

statins 497, 1562

steroid switch 2248

steroid-induced diabetes 628

steroids 1249

STMN1 1180

stomach 1993

stool biomarker 1765

STR profiling 1021

stroma 1917

stromal fibroblasts 1625

STX2484 300

SUMO 1688

sunitinib 1047, 2254

sunitinib resistance 1168

survival 157, 174, 181, 255, 461, 470, 589, 619, 623, 628, 1004, 1102, 1363, 1373, 1526, 1581, 1860, 2172

survivorship care plan 1899

SV2C 1241

symptom screening 1262

syndecan-1 1965

T cells 823, 866

TACA 1634

tamoxifen 1836

tandem mass spectrometry 799

target therapy 2122

targeted agents 1047, 1305

targeted clinical trials 1881

targeted therapeutics 85, 2033

taxane resistance 300

TBLR1 112

TCGA 2297

teenage and young adult cancer 1814

TERT promoter mutation 2024

Tetranucleotide repeats 823

textile industry 603

TGF-β 1230

TGF-β1 signalling pathway 772

therapeutic response 1802

therapeutic targeting 515, 1255, 1780

therapy 756

thyroid cancer 551

time dependency 2242

TIMP-1 1772

tissue microarray 309, 1363, 1373, 1977

TMZ 2275

TNF 1581

TNF-α 1955

topoisomerase 1 1319

TP53 823, 1213, 2351

trabectedin 646

TRAIL 1955

transcription-coupled repair 1293

trastuzumab 660, 1065, 1888

trastuzumab resistance 689

trastuzumab-DM1 1888

treatment decision making 674

treatment delay 461

treatment outcome 444

treatment trade-off method 674

tremelimumab 2214

triage test 1095

triple-negative breast cancer 2051, 2328

trough concentration 1909

tubulin 300

tumour biomarker 1065

tumour board recommendation 837

tumour endothelial markers (TEM) 149

tumour growth and metastasis 736

tumour heterogeneity 1201

tumour interstitial fluid 559

tumour microenvironment 157, 927, 1350, 1625

Tumour Necrosis Factor (TNFα) 1688

tumour progression 2003

tumour stroma 157

tumour suppressor 386

tumour-infiltrating lymphocytes 1350

type 2 diabetes 2180

type X 598

type-I endometrial cancer 987

tyrosine kinase inhibitors 1750

tyrosine kinase receptor 407

uPA 139

upper aerodigestive tract cancer 1852

urinary biomarker 1772

urinary bladder cancer 1180

urinary bladder neoplasms 444

uterine serous cancer 1750

UV radiation 1810

uveal melanoma 1373

vaccine 1824

vaginal brachytherapy 674

validation 470

VEGF-signalling inhibitors 1590

vemurafenib 640, 1625

vitamin D intake 976

vitamin D supplements 976

vitamin supplement 2220

volatile organic compound 790

von Willebrand factor 1742

Withacnistin 894

withdrawal response 2046

Wnt/β-catenin signalling 132

XELOX 241

xenograft 365

zoledronic acid 1139